SCHEMBL6634743

SCHEMBL6634743

O=C(c1ccccc1)N1CCC2(CCCNC2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.60
L3MBTL3 Q96JM7 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
SIGMAR1 Q99720 1/20 0.58
NAMPT P43490 3/20 0.57
CHRM2 P08172 1/20 0.53
CHRM3 P20309 1/20 0.53
HPGD P15428 1/20 0.53
USP2 O75604 1/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
GABRD O14764 1/20 0.51
GABRA1 P14867 1/20 0.51
GABRB1 P18505 1/20 0.51
GABRA5 P31644 1/20 0.51
GABRA3 P34903 1/20 0.51
GABRA2 P47869 1/20 0.51
GABRB2 P47870 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6631344 0.92 HSD17B10 (0.67) HSD17B10L3MBTL3L3MBTL1SIGMAR1NAMPT
SCHEMBL6631346 0.91 L3MBTL3 (0.64) L3MBTL3L3MBTL1SIGMAR1NAMPTCHRM2
SCHEMBL17888418 0.86 GABRD (0.71) HSD17B10L3MBTL3L3MBTL1NAMPTHPGD
SCHEMBL14742135 0.83 NAMPT (0.66) HSD17B10L3MBTL3L3MBTL1SIGMAR1NAMPT
SCHEMBL21077977 0.83 L3MBTL3 (0.56) HSD17B10L3MBTL3L3MBTL1NAMPTUSP2
SCHEMBL17886797 0.83 HPGD (0.61) HSD17B10L3MBTL3L3MBTL1NAMPTHPGD
SCHEMBL5436686 0.82 GABRD (0.73) SIGMAR1NAMPTCHRM2CHRM3CYP1A2
SCHEMBL7170178 0.81 NAMPT (0.67) HSD17B10L3MBTL3L3MBTL1SIGMAR1NAMPT
SCHEMBL17888477 0.79 GABRD (0.64) HSD17B10L3MBTL3L3MBTL1NAMPTUSP2
SCHEMBL2819024 0.78 HSD17B10 (0.52) HSD17B10L3MBTL3L3MBTL1NAMPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854869-B1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION LILLY CO ELI (US) 2004-08-25 EP disclosed
US-6528534-B2 Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes MILLENNIUM PHARMACEUTICALS, INC. 2003-03-04 US disclosed
US-20020013325-A1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation FISHER MATTHEW J (US) 2002-01-31 US disclosed
US-6291469-B1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation ELI LILLY AND COMPANY 2001-09-18 US disclosed
EP-0854869-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1998-07-29 EP disclosed
WO-1997011940-A1 SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1997-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013325-A1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, SELP HSD17B10 1401/4885L3MBTL3 4859/4885L3MBTL1 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.